98 results about "Glaucoma" patented technology

The invention discloses a retina thickness prediction method and system based on a multi-modal image, and the method and system achieve the effective estimation of the retina thickness under a low-cost condition through feature alignment and fusion modeling, and improve the basic screening and follow-up visit capability. According to the invention, through fusion of the multi-mode retina image data, the structure and function information of the optic nerve can be more comprehensively obtained, and the prediction accuracy of the thickness of the retina nerve fiber layer (RNFL) is improved. The OCT high-resolution hierarchical structure and the wide-view texture features of the eye fundus image are combined, so that anatomy and pathological states of optic nerves can be truly restored. The method can be used as an auxiliary method for early screening and early warning of optic neurodegenerative diseases such as glaucoma, and provides support for low-cost and high-efficiency primary screening and clinical auxiliary decision making.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

The invention relates to the technical field of visual function diagnosis, and provides a visual function examination device based on eye movement tracking, a medium and computer equipment, the device comprises a data acquisition unit, an eye movement evaluation unit, a visual field evaluation unit and a comprehensive analysis unit, the data acquisition unit is used for acquiring visual function data of an examinee, and the comprehensive analysis unit is used for analyzing the visual function data of the examinee; the eye movement evaluation unit evaluates an eye movement function based on eye movement parameters in the visual function data; the visual field evaluation unit evaluates a visual field function based on visual field parameters in the visual function data; according to the application, objective sight drop points are used for replacing subjective keys, false negative and false positive are reduced, before typical defects do not appear in the visual field, early visual function changes can be prompted through eye movement parameter abnormity, auxiliary screening of early glaucoma and other diseases is achieved, and the visual function detection accuracy is improved. Meanwhile, the diagnosis accuracy is improved through double evidences of eye movement and visual field in the middle and late stages, and the sensitivity and specificity of visual function examination are remarkably improved on the whole.

Provided is a composition for visual field defect disorders, glaucoma, light-induced ocular tissue damage and related disorders, which can be used as a food or drug for long-term administration, prevention, symptom relief and improvement. A composition comprising a triglyceride represented by the formula (I):(wherein R1, R2, and R3 are each a saturated fatty acid residue, and at least one of them is a pentadecanoic acid residue) as an active ingredient.

The invention relates to an intelligent nursing and monitoring device used after glaucoma filtration, and belongs to the technical field of medical instruments, the intelligent nursing and monitoring device comprises a rigid main frame, the inner side of the rigid main frame is provided with a flexible sealing gasket, the upper portion of the rigid main frame is integrated with a self-adaptive positioning system, and the left side and the right side of the rigid main frame are connected with directional physical nursing execution systems; a microenvironment humidity monitoring system is embedded in the ball head, and the rear side of the frame is connected with an intelligent central control system. The self-adaptive positioning system accurately recognizes eyeball and filtered bubble areas, the directional physical nursing execution system reproduces standardized nursing operation, the microenvironment humidity monitoring system verifies the nursing effect in real time, and the intelligent central control system overall plans all the systems to cooperate and supports remote data transmission. The device can solve the problems of inaccurate postoperative nursing, lagged effect feedback and poor patient compliance, improves the nursing quality, assists in improving the success rate of an operation, and is suitable for families and clinical nursing scenes.

This document provides methods and compositions for neuroprotection. The neuroprotective composition may be or include cannabinol or a derivative thereof. The neuroprotective composition may be used in the treatment of neurodegenerative diseases. It may be used to protect retinal neurons from degeneration in individuals who require it, such as in the treatment of glaucoma.

A system may include a headset device comprising a display screen and an adaptive map perimetry algorithm that is configured to access or implement a normative database or model. The system may implement a VF test adapted to fit an area of the display screen based on values in the normative database or model and is rendered as a same or similar visualization compared to one or more different headset devices having different display screens having different respective shapes, formats, sizes, and / or resolutions. The system may receive visual test data indicating a visual field of the user and detect one or more initial test locations. The one or more initial test locations define one or more healthy clusters indicative of an absence of scatoma and one or more damaged clusters indicative of scotoma. The system may generate a spatial mapping identifying locations of the one or more damaged clusters.

The invention provides a glaucoma visual field progress prediction device and electronic equipment, and the method comprises the steps: obtaining a first original fundus image feature, a second original fundus image feature and primary clinical text data through preprocessing, and enabling the second original fundus image to be overturned relative to the first original fundus image; the twin bilateral difference network obtains bilateral blood vessel difference features of the first original eye fundus image features and the second original eye fundus image features, the bilateral blood vessel difference features and the first original image features are fused, and the text guide image feature enhancement module guides enhancement of image features output by the twin bilateral difference network through clinical text features. According to the glaucoma visual field progress prediction method and device, the trained prediction device is utilized to realize intelligent prediction of the glaucoma visual field progress, so that the problems of insufficient judgment accuracy, time consumption and low efficiency caused by dependence on subjective experience are avoided, and the prediction accuracy and timeliness are improved.

The application relates to the technical field of glaucoma grading, and discloses a glaucoma grading system based on multi-modal conditional state space fusion, which comprises the following steps: acquiring CFP images and OCT images, constructing a glaucoma grading network model, the model comprising a circular structure perception attention module, a layer prior enhanced axial attention module and a conditional state space fusion module; the circular structure perception attention module enhances the representation ability of a circular key pathological change region in the CFP image; the layer prior enhanced axial attention module enhances the utilization of key pathological change information in the OCT image; the conditional state space fusion module dynamically modulates the CFP spatial features through OCT global information, realizes cross-modal feature interaction, and uses the trained network model to perform glaucoma grading. The application can effectively fuse multi-modal information, enhance the feature extraction capability of glaucoma-related pathological features, and improve the performance of glaucoma grading.

Pharmaceutical compositions are disclosed in the form of orosoluble suckable and chewable tablets consisting of citicoline, nicotinamide and pharmaceutically acceptable excipients, for use in the prevention and / or treatment of degeneration of the optic nerve and retinal nerve cells resulting from glaucoma.

A system includes a first light source configured to emit visible light according to one or more first parameters and a second light source configured to emit treatment light for altering patient tissue. A surgical instrument includes a distal portion configured to insert within an eye of a patient and an optical fiber conducts light from the first and second light sources to a tip of the distal portion. One or more sensors are configured to detect a state of the tip of the distal portion relative to the patient tissue. A controller is coupled to the one or more sensors, the first light source, and the second light source. The controller is configured to select values for the one or more first parameters according to the state of the tip of the distal portion relative to the patient tissue.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

A glaucoma drainage tube and its manufacturing process are disclosed, relating to the field of ophthalmic medical device technology. The tube is manufactured using a drainage tube manufacturing device, which includes a negative electrode, a positive electrode, and a power source. The negative electrode comprises a middle section and a terminal section, with the outer surface of the terminal section being trumpet-shaped. The negative electrode consists of two interlocking parts. The distance between the central axis of the middle section and the positive electrode is 0.3–2 cm. The positive and negative terminals of the power source are connected to the negative and positive electrodes, respectively. The manufacturing process includes the following steps: providing an acidic electrolyte; placing the working electrode and the positive electrode in the electrolyte for an electrochemical reaction to form a collagen film on the circumferential surface of the working electrode, obtaining a preliminary product; cross-linking the preliminary product; and then extracting the two parts of the negative electrode from within the collagen film towards the terminal section, respectively, to obtain the glaucoma drainage tube. This method can produce a glaucoma drainage tube with trumpet-shaped ends, improving the problem of easy displacement of existing glaucoma drainage tubes after implantation into the eye.

Antibodies that specifically bind to TrkB and methods of use thereof are disclosed. Agonist antibodies having neuroprotective effects, as shown by their ability to enhance retinal ganglion cell survival in vitro, are disclosed, and these agonist antibodies can be used in the treatment of conditions such as eye diseases, including glaucoma. In addition, other neuronal diseases or conditions can also benefit from treatment with these agonist antibodies, including those characterized in part by neuronal damage. In certain embodiments, the present invention includes antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention can be fully human, non-naturally occurring antibodies formulated with an excipient for injection.

The application discloses a kind of compositions and applications for regenerating retinal ganglion cells by using endogenous microglia.The present application finds that multiple genes (Brn3b, Sox2, Cbln1 and NP1, referred to as BSCN) can be expressed in microglia to transform into retinal ganglion cells by in vivo microglia fate lineage tracking.The regenerated ganglion cells project axons to the distant brain, rebuild visual neural circuit and restore impaired vision in adult glaucoma mice.In addition, the regenerated ganglion cells can stably survive for up to one year, and the same regeneration strategy is used in old glaucoma mice, which confirms the effectiveness of BSCN reprogramming to regenerate RGCs.Therefore, the present application determines that microglia is a new type of reprogramming seed cell, and finds that four key genes are involved in RGCs regeneration to restore vision, which provides a new therapeutic drug and means for the treatment of glaucoma and related diseases.

A system may include a head-mounted display device and an average visual hill (HoV) model, and may also generate an eye difference estimate relative to average healthy human eye reference data acquired from a standard data set. The ocular difference estimate indicates an overall sensitivity or overall height relative to the reference data, and a difference in sensitivity over a rate at which eccentricity decays. According to the system, a personalized HoV model can be generated based on an eye difference estimation value and an average HoV model; respectively displaying corresponding stimulation signals at a plurality of test positions of the head-mounted display device; storing response data of the test object to the stimulation signal; and by analyzing the response data, determining a sensitivity value corresponding to each position of the test object in the plurality of test positions. The system may also determine a total deviation value for the test object by subtracting the sensitivity value for each response in the plurality of test locations from the respective values of the personalized HoV model, analyze the total deviation value, and provide feedback based on the analysis.

The invention discloses a multi-mode glaucoma detection method, a medium and a system. The method comprises the following steps: acquiring original multi-mode data corresponding to a sample to be detected; outputting a first branch feature corresponding to the fundus image data, a second branch feature corresponding to the optical coherence tomography data and a third branch feature corresponding to the thickness image data through a backbone network; applying bidirectional cross attention to the first branch feature and the third branch feature to obtain cross attention results corresponding to the first branch feature and the third branch feature; performing gating fusion based on the cross attention result and the first branch feature to obtain a fusion representation, and inputting the fusion representation into a classification head to predict a classification result corresponding to the to-be-detected sample through the classification head; the glaucoma can be effectively detected based on multi-modal data, and the accuracy and the reference of a glaucoma detection result are improved.

The present application provides an acesulfame implant which is stable, safe and can achieve at least 6 months of sustained release, can effectively treat various eye diseases including but not limited to glaucoma, cataract, retinal vein obstruction (RVO), uveitis, diabetic macular edema (DME) and age-related macular degeneration (wAMD and nAMD), etc., avoids repeated administration, reduces the formation of side effects, reduces the cost of drug use, and meets the high stability required by drug preparation in production, storage and transportation, has good application prospect, and meets the unmet clinical needs.

The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabinoids to target sites, including sites on the surface of and / or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and / or to treat ophthalmic conditions such as glaucoma.

The invention relates to the technical field of eye protection liquid, in particular to a preparation method of eye care health-care liquid, which is prepared from the following raw materials in parts by mass: 5 to 7 parts of blueberry fruit, 15 to 17 parts of cowberry fruit and 9 to 11 parts of resveratrol. The preparation method comprises the following steps: S1, cleaning prepared blueberry fruits, steaming the cleaned blueberry fruits in a high-pressure steamer to obtain cooked blueberry fruits, and then extruding and cooking the cooked blueberry fruits to obtain blueberry fruit juice for later use; s2, cleaning the prepared bilberry fruits, soaking the bilberry fruits in 10-12% saline water for 10-12 hours, and then extruding to obtain bilberry juice for later use; and S3, mixing the cooked blueberry fruit juice, the cowberry fruit juice and the resveratrol obtained in the previous step to obtain the required eye care health-care liquid. The eye care health-care liquid has the remarkable advantages of treating dry eyes, muscae volitantes, glaucoma, presbyopia and the like.

The invention discloses a glaucoma internal aqueous humor drainage support and relates to the technical field of medical instruments.The drainage support comprises a support body, a drainage piece and an adjusting assembly, the first end of the support body is a blind end, the second end of the support body is provided with an opening, a drainage channel communicated with the opening is formed in the support body in a penetrating mode, and the first end of the support body is provided with an open window; the drainage part is arranged in the support body and located below the window, an installation groove is formed in the drainage part, a through drainage hole is formed in the installation groove and communicated with the drainage channel and the window, and the adjusting assembly is arranged on the installation groove and used for adjusting the opening area of the drainage hole. The size of the opening area of the drainage hole is adjusted through the adjusting assembly, the opening area of the drainage hole can be adjusted according to the eye pressure, and the adjusting accuracy of the eye pressure is guaranteed.

The present invention recognizes that medical devices, such as contact lenses, can be made having at least one coating layer provide drug storage and drug release for the treatment of various diseases, disorders, or conditions. One aspect includes a packaged medical device including a medicament. Another aspect includes a drug delivery contact lens. A further aspect includes a method of making a drug delivery contact lens. An additional aspect includes a method of using a drug delivery contact lens. A further aspect includes a medical device including bimatoprost and N-vinylpyrrolidone. An additional aspect includes a contact lens soaking solution. Another aspect includes a method of loading contact lenses. Another aspect includes loaded and refreshed contact lenses. A further aspect includes methods of using loaded and refreshed contact lenses.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The invention relates to methods for determining the stage of a disease, particularly an ocular neurodegenerative disease such as Alzheimer's, Parkinson's, Huntington's and glaucoma, comprising the steps of identifying the status of microglial cells in the retina and relating that status to disease stage. Methods for identifying cells in the eye are also provided, as are labelled markers and the use thereof.

The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.

A system may include a headset device and an average hill of vision model (HoV) and may generate an eye difference estimate relative to reference data for an average healthy eye obtained from a normative dataset. The eye difference estimate indicates a difference in overall sensitivity or general height and the rate of sensitivity decay with eccentricity relative to the reference data. The system may generate an individualized HoV model based on the eye difference estimate and the average HoV model, display, on the headset device, a respective stimulus at a plurality of test locations, store responses to the stimulus, and analyze the responses to determine a respective sensitivity value at each of the plurality of test locations. The system may determine total-deviation values by subtracting the respective sensitivity value from a corresponding value of the individualized HoV model, analyze the total-deviation values, and provide feedback based on the analysis.

The present invention provides an edible composition for alleviating visual fatigue. The composition comprises in parts by weight 1 to 10 parts of curcuma powder, 1 to 12 parts of whole coffee fruit extract, 1 to 20 parts of phospholipid composite, 1 to 15 parts of DHA, 0.5 to 5 parts of phosphatidylserine, and 0.1 to 5 parts of vitamin C. After one week of trial consumption by the subject, the duration of photopic vision is improved with a significant difference in comparison with that before the trial; after 2 weeks of trial consumption, the overall score of visual fatigue symptoms decreases with a significant difference in comparison with that before the trial; after 8 weeks of trial consumption by the subject, the vision field thereof is remarkably enlarged, indicating the formulation may prevent the occurrence of glaucoma. The coffee extract combined with the remaining ingredients has a synergistic effect.

The present invention pertains to new compounds, possessing unique structural features, effective in blue light absorption. The compounds, named as Cordylutenes, show significant biological activity in the prevention and / or treatment of blue light-induced ocular damage. Also provided includes a method and a pharmaceutical, cosmetical or edible composition for preventing or treating an ocular disease, such as dry eye disease, cataracts, glaucoma, or macular degeneration, comprising the Cordylutenes or a pharmaceutically, cosmetically, or edibly acceptable salt thereof.

The application discloses a screening method and a screening device for distinguishing early glaucoma patients. The screening method comprises the following steps: wearing a VR device by a subject and calibrating a gaze point, displaying a pre-detection scene image to collect eye movement and head movement data for calibration, then displaying a detection scene image and collecting corresponding data. After the data is combined based on time points, it is substituted into a glaucoma-normal person classification model for evaluation, so that whether the subject has glaucoma characteristics is judged. The screening method and the screening device provided by the application can effectively distinguish early glaucoma patients by analyzing the eye movement and head movement characteristics of the subject based on a virtual reality device, establishing a characteristic model of glaucoma patients, and providing technical support for early screening.